Total Payments
$161,980
2024 Payments
$39,085
Companies
13
Transactions
156
Medicare Patients
764
Medicare Billing
$128,138
Payment Breakdown by Category
Consulting$108,743 (67.1%)
Travel$43,589 (26.9%)
Food & Beverage$4,382 (2.7%)
Research$3,300 (2.0%)
Other$1,960 (1.2%)
Education$5.56 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $108,743 | 24 | 67.1% |
| Travel and Lodging | $43,589 | 65 | 26.9% |
| Food and Beverage | $4,382 | 60 | 2.7% |
| Unspecified | $3,300 | 2 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,960 | 4 | 1.2% |
| Education | $5.56 | 1 | 0.0% |
Payments by Type
General
$158,680
154 transactions
Research
$3,300
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $76,483 | 70 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $22,479 | 22 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $17,289 | 32 | $0 (2021) |
| F. Hoffmann-La Roche AG | $16,152 | 9 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $8,500 | 1 | $0 (2022) |
| Genentech, Inc. | $6,890 | 8 | $0 (2018) |
| PFIZER INC. | $6,660 | 6 | $0 (2022) |
| ABBVIE INC. | $3,081 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,950 | 1 | $0 (2021) |
| Eisai Inc. | $1,875 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,085 | 35 | Merck Sharp & Dohme LLC ($25,599) |
| 2023 | $23,303 | 21 | Merck Sharp & Dohme LLC ($23,200) |
| 2022 | $27,338 | 18 | SERVIER PHARMACEUTICALS LLC ($8,500) |
| 2021 | $6,700 | 4 | GlaxoSmithKline, LLC. ($1,950) |
| 2020 | $14,154 | 8 | Novartis Pharmaceuticals Corporation ($7,304) |
| 2019 | $16,827 | 26 | E.R. Squibb & Sons, L.L.C. ($8,003) |
| 2018 | $8,681 | 10 | Genentech, Inc. ($6,640) |
| 2017 | $25,890 | 34 | Merck Sharp & Dohme Corporation ($9,612) |
All Payment Transactions
156 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $915.00 | General |
| Category: VACCINE | ||||||
| 06/26/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 06/11/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,081.25 | General |
| 06/02/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $584.17 | General |
| 05/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $83.67 | General |
| 05/06/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $12,200.00 | General |
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $8,521.78 | General |
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $1,355.19 | General |
| 04/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $1,154.71 | General |
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $279.46 | General |
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $147.27 | General |
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $101.64 | General |
| 04/10/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $71.99 | General |
| 04/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 03/28/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $265.00 | General |
| 03/28/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.90 | General |
| 03/28/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $59.86 | General |
| 03/28/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.90 | General |
| 03/27/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $265.00 | General |
| 03/27/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $211.70 | General |
| 03/27/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $149.61 | General |
| 03/27/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.90 | General |
| 03/27/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $59.86 | General |
| 03/27/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.90 | General |
| 03/26/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $265.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A PHASE 1A/1B STUDY OF LY3435151 ADMINISTERED TO PATIENTS WITH ADVANCED SOLID TUMORS | Eli Lilly and Company | $100.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 181 | 347 | $157,037 | $30,891 |
| 2022 | 6 | 190 | 375 | $169,743 | $34,189 |
| 2021 | 5 | 193 | 363 | $144,845 | $35,363 |
| 2020 | 7 | 200 | 366 | $113,186 | $27,694 |
Total Patients
764
Total Services
1,451
Medicare Billing
$128,138
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 90 | 200 | $81,625 | $16,520 | 20.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 38 | $27,900 | $4,657 | 16.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 62 | $17,236 | $4,187 | 24.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $20,404 | $3,533 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 17 | 24 | $9,872 | $1,993 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 92 | 192 | $76,820 | $15,802 | 20.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 97 | $38,703 | $8,449 | 21.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $26,817 | $4,913 | 18.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 22 | 28 | $19,964 | $3,525 | 17.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 13 | 13 | $3,653 | $806.12 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 14 | $3,786 | $694.51 | 18.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 107 | 253 | $85,107 | $21,824 | 25.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 38 | 38 | $27,604 | $6,148 | 22.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 23 | 39 | $23,611 | $5,015 | 21.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 12 | 15 | $4,257 | $1,313 | 30.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 18 | $4,266 | $1,063 | 24.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 91 | 206 | $56,434 | $13,501 | 23.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 49 | $16,898 | $4,440 | 26.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 27 | 27 | $15,732 | $3,849 | 24.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 17 | 24 | $11,604 | $2,270 | 19.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 27 | 31 | $6,511 | $2,155 | 33.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 16 | 18 | $3,286 | $769.80 | 23.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 11 | 11 | $2,721 | $709.35 | 26.1% |
About Dr. Patrick Ott, MD
Dr. Patrick Ott, MD is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1871792218.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Ott, MD has received a total of $161,980 in payments from pharmaceutical and medical device companies, with $39,085 received in 2024. These payments were reported across 156 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($108,743).
As a Medicare-enrolled provider, Ott has provided services to 764 Medicare beneficiaries, totaling 1,451 services with total Medicare billing of $128,138. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Boston, MA
- Active Since 07/16/2007
- Last Updated 10/29/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1871792218
Products in Payments
- MEKINIST (Drug) $17,248
- KEYTRUDA (Biological) $11,646
- Actemra (Biological) $6,640
- TAFINLAR (Drug) $4,885
- Lenvima (Drug) $1,875
- OPDIVO (Biological) $1,625
- Non-Covered Product (Drug) $250.09
- FOUNDATIONONE CDX (Device) $229.00
- MEKTOVI (Drug) $194.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701